Literature DB >> 26474448

Persistent Tachypnea of Infancy. Usual and Aberrant.

Daniela Rauch1, Martin Wetzke2, Simone Reu3, Waltraud Wesselak1, Andrea Schams1, Meike Hengst1, Birgit Kammer1, Julia Ley-Zaporozhan1, Matthias Kappler1, Marijke Proesmans4, Joanna Lange5, Amparo Escribano6, Eitan Kerem7, Frank Ahrens8, Frank Brasch9, Nicolaus Schwerk3, Matthias Griese1.   

Abstract

RATIONALE: Persistent tachypnea of infancy (PTI) is a specific clinical entity of undefined etiology comprising the two diseases neuroendocrine cell hyperplasia of infancy (NEHI) and pulmonary interstitial glycogenosis. The outcome of typical NEHI is favorable. The outcome may be different for patients without a typical NEHI presentation, and thus a lung biopsy to differentiate the diseases is indicated.
OBJECTIVES: To determine whether infants with the characteristic clinical presentation and computed tomographic (CT) imaging of NEHI (referred to as "usual PTI") have long-term outcome and biopsy findings similar to those of infants with an aberrant presentation and/or with additional localized minor CT findings (referred to as "aberrant PTI").
METHODS: In a retrospective cohort study, 89 infants with PTI were diagnosed on the basis of clinical symptoms and, if available, CT scans and lung biopsies. Long-term outcome in childhood was measured on the basis of current status.
MEASUREMENTS AND MAIN RESULTS: Infants with usual PTI had the same respiratory and overall outcomes during follow-up of up to 12 years (mean, 3.8 yr) as infants who had some additional localized minor findings (aberrant PTI) visualized on CT images. Both usual and aberrant PTI had a relatively favorable prognosis, with 50% of the subjects fully recovered by age 2.6 years. None of the infants died during the study period. This was independent of the presence or absence of histological examination.
CONCLUSIONS: PTI can be diagnosed on the basis of typical history taking, clinical findings, and a high-quality CT scan. Further diagnostic measures, including lung biopsies, may be limited to rare, complicated cases, reducing the need for an invasive and potentially harmful procedure.

Entities:  

Keywords:  children’s interstitial lung disease; diffuse parenchymal lung disease; infants; neuroendocrine cell hyperplasia of infancy; pulmonary interstitial glycogenosis

Mesh:

Year:  2016        PMID: 26474448     DOI: 10.1164/rccm.201508-1655OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  11 in total

Review 1.  Interstitial lung disease in newborns.

Authors:  Lawrence M Nogee
Journal:  Semin Fetal Neonatal Med       Date:  2017-03-28       Impact factor: 3.926

2.  High-resolution CT findings of pulmonary interstitial glycogenosis.

Authors:  Jason P Weinman; Christina J White; Deborah R Liptzin; Robin R Deterding; Csaba Galambos; Lorna P Browne
Journal:  Pediatr Radiol       Date:  2018-04-23

Review 3.  Approaching Clinical Trials in Childhood Interstitial Lung Disease and Pediatric Pulmonary Fibrosis.

Authors:  Robin R Deterding; Emily M DeBoer; Michal J Cidon; Terry E Robinson; David Warburton; Gail H Deutsch; Lisa R Young
Journal:  Am J Respir Crit Care Med       Date:  2019-11-15       Impact factor: 21.405

4.  Growth trajectories and oxygen use in neuroendocrine cell hyperplasia of infancy.

Authors:  Rebekah J Nevel; Errine T Garnett; Deneen A Schaudies; Lisa R Young
Journal:  Pediatr Pulmonol       Date:  2018-02-02

5.  Pulmonary interstitial glycogenosis: Diagnostic evaluation and clinical course.

Authors:  Deborah R Liptzin; Christopher D Baker; Jeffrey R Darst; Jason P Weinman; Megan K Dishop; Csaba Galambos; John T Brinton; Robin R Deterding
Journal:  Pediatr Pulmonol       Date:  2018-07-18

6.  Childhood interstitial lung diseases in immunocompetent children in Australia and New Zealand: a decade's experience.

Authors:  Vishal Saddi; Sean Beggs; Bruce Bennetts; Joanne Harrison; Neil Hime; Nitin Kapur; Jill Lipsett; Lawrence M Nogee; Amy Phu; Sadasivam Suresh; André Schultz; Hiran Selvadurai; Stephanie Sherrard; Roxanne Strachan; Julian Vyas; Yvonne Zurynski; Adam Jaffé
Journal:  Orphanet J Rare Dis       Date:  2017-07-25       Impact factor: 4.123

7.  Role of High-Resolution Chest Computed Tomography in a Child with Persistent Tachypnoea and Intercostal Retractions: A Case Report of Neuroendocrine Cell Hyperplasia.

Authors:  Mara Lelii; Maria Francesca Patria; Raffaella Pinzani; Rossana Tenconi; Alessandro Mori; Nicola Bonelli; Nicola Principi; Susanna Esposito
Journal:  Int J Environ Res Public Health       Date:  2017-09-25       Impact factor: 3.390

8.  Identifying Biomarkers in Pediatric Rare Lung Disease. chILD Grows Up.

Authors:  Timothy J Vece; Charles R Esther
Journal:  Am J Respir Crit Care Med       Date:  2019-12-15       Impact factor: 21.405

9.  Neuroendocrine cell hyperplasia of infancy: an unusual cause of hypoxemia in children.

Authors:  Silvia Caimmi; Amelia Licari; Davide Caimmi; Anna Rispoli; Eugenio Baraldi; Fiorella Calabrese; Gian Luigi Marseglia
Journal:  Ital J Pediatr       Date:  2016-09-15       Impact factor: 2.638

Review 10.  Childhood rare lung disease in the 21st century: "-omics" technology advances accelerating discovery.

Authors:  Timothy J Vece; Jennifer A Wambach; James S Hagood
Journal:  Pediatr Pulmonol       Date:  2020-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.